Welcome to our dedicated page for JOINT SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Joint Corp. filings document the regulatory record for a public chiropractic-care franchisor and clinic operator. Its 8-K reports cover operating and financial results, earnings presentations, material agreements, and capital-structure matters tied to credit facilities, covenants, restricted payments, and share repurchase capacity.
Proxy and governance filings describe director elections, board nomination matters, executive compensation, equity awards, shareholder voting items, and common-stock ownership disclosures. The company’s formal filings also record agreements related to corporate governance and the financing structure that supports its franchise-focused clinic network.
The Joint Corp. reported results from its 2026 annual stockholder meeting held on May 20, 2026. Stockholders elected seven directors to serve until the 2027 annual meeting, with each nominee receiving over 9.8 million votes in favor and substantial support relative to votes against.
Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers and supported holding this advisory vote on executive pay every year. They also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026, with more than 12.7 million votes in favor.
JOINT Corp ownership update: Charles E. Jobson filed an Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 1,793,854 shares of Common Stock, representing 12.52% of the class. The filing states Mr. Jobson has sole voting and sole dispositive power over these shares. The filing is signed by Charles E. Jobson on 05/15/2026.
JOINT Corp major shareholder Charles E. Jobson increased his stake through open-market buying. He purchased a total of 148,051 shares of common stock on May 12–13 at a price of $8.57 per share. After these purchases, he directly owns 1,793,854 common shares of JOINT Corp, reflecting continued direct exposure as a more than ten percent owner.
The Joint Corp. reported first-quarter 2026 results with continuing-operations revenue of $14.8 million, up from $13.1 million a year earlier, and net income of $1.3 million versus $1.0 million.
Continuing operations swung to a $1.1 million profit from a prior-year loss as franchising and fee-based revenues grew while costs stayed controlled. The corporate clinic segment is classified as discontinued operations as the company pursues a major refranchising strategy; revenue from those clinics fell to $9.4 million from $16.9 million, reflecting progress on clinic sales. Cash and cash equivalents were $20.7 million, with total assets of $57.9 million and liabilities of $42.4 million. The company repurchased $1.1 million of stock under its buyback program and ended the quarter with 868 franchised clinics and 943 total clinics in operation.
The Joint Corp. reported stronger first-quarter 2026 results while amending its credit facility and advancing its refranchising strategy. Revenue from continuing operations rose 13% to $14.8 million, and consolidated net income increased 34% to $1.3 million, or $0.09 per diluted share. Net income from continuing operations was $1.1 million, a turnaround from a loss of $0.5 million a year earlier, and consolidated Adjusted EBITDA grew 22% to $3.5 million.
System-wide sales were $126.1 million, down 4.9%, with comp sales down 4.2%. Free cash flow improved to $(1.7) million from $(4.0) million, and unrestricted cash totaled $20.7 million with a fully undrawn $20 million credit line. The company repurchased 137,000 shares for $1.1 million.
The company signed an agreement to sell 45 company-owned or managed clinics and a letter of intent to sell five more, leaving only three clinics company-owned or managed after completion. It reiterated 2026 guidance for system-wide sales of $519–$552 million, consolidated Adjusted EBITDA of $12.5–$13.5 million, and 30–35 new franchised clinic openings.
The Joint Corp. has signed and begun executing an Asset Purchase Agreement to sell 45 company-owned or managed clinics in Southern California to Elite Chiro Group for approximately $2.3 million. On April 27, 2026, ownership of 13 clinics transferred, while Elite Chiro Group assumed operations of the remaining 32 clinics under a Management Service Agreement until lease assignments are completed.
Upon completion of this transaction and two previously announced refranchising agreements, the company expects to operate only three corporate-managed clinics out of 960 locations, effectively shifting to a capital-light, pure-play franchisor model focused on supporting franchisee growth.
The Joint Corp. signed an Asset Purchase Agreement to sell the assets of, and grant franchise rights for, 45 company-owned or managed clinics in Southern California to Elite Chiro Group for an aggregate purchase price of $2.3 million, subject to adjustments.
The price includes prorated franchise fees across 45 new franchise agreements and non-exclusive development rights for 10 additional clinics in agreed metropolitan areas. Elite Chiro Group will pay a non-refundable $150,000 down payment for exclusivity, with the remaining amount placed in escrow and released as each clinic closes. Each clinic closing depends on assignment of its existing lease and other customary closing conditions.
JOINT Corp filed Amendment No. 3 to a Schedule 13G/A reporting Charles E. Jobson's beneficial ownership of 11.4% of the company's Common stock, equal to 1,645,803 shares.
The filing lists Mr. Jobson with sole voting and sole dispositive power over 1,645,803 shares. The filing shows CUSIP 47973J102 and is signed on 04/23/2026.
JOINT Corp disclosed that 10% owner Charles E. Jobson made an open-market purchase of common stock. On April 21, 2026, he bought 509 shares at $8.58 per share. Following this transaction, he directly holds 1,645,803 common shares of JOINT Corp.
The Joint Corp. is asking stockholders to vote at its virtual 2026 annual meeting while highlighting a return to profitability and a shift to a pure-play franchisor model. The proxy outlines seven director nominees, advisory votes on executive pay and its frequency, and auditor ratification.
In 2025, consolidated revenue reached $54.9 million, up from $52.2 million, with net income of $2.9 million compared to a $5.8 million loss in 2024. Consolidated Adjusted EBITDA rose to $13.0 million and system-wide sales were $532.4 million, a 0.4% increase.
The company refranchised 41 clinics, signed agreements covering 22 more, and closed nine, ending 2025 with 960 clinics, of which 885 were franchised. It repurchased 1.3 million shares for $11.3 million and generated $1.8 million of operating cash flow, while projecting higher-margin, asset-light economics once refranchising is completed.